1. Pink Sheet
  2. >>Compliance
  3. >>Marketing & Advertising

Digesting Caronia

 
• By Michael McCaughan

A December appellate court ruling in an off-label promotion case prompted headlines about sweeping implications for FDA’s regulatory authority. How does the ruling look four months later?

Every year, the Food & Drug Law Institute compiles a top 20 list of the most important FDA cases decided in the preceding 12 months. The list is not ranked; rather it provides a framework to support the association’s overall mission of serving as a resource for lawyers who practice in all areas of food and drug law.

Still, based on the agenda for FDLI’s 2013 annual meeting in Washington DC, there is no doubt which case ranked...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Marketing & Advertising

Industry Rethinking Visual Elements And Quality-Of-Life Claims After US FDA Drug Ad Crackdown

 
• By Sue Sutter

Sponsors should consider whether their TV commercials contain the same number of scene changes during the major statement as ads that received a violation letter.

Legal ‘Squishiness,’ DoJ Reorganization Could Shape Ad/Promo Enforcement Strategy

 
• By Sue Sutter

The extent of FDA and Justice Department coordination on recent warning and untitled letters is unclear, but the “squishy” issues cited in many of the letters and recent elimination of DoJ’s Consumer Protection Branch could influence legal action, industry lawyers said.

US FDA Ad/Promo Crackdown Letters Came From OPDP Staff, Not Artificial Intelligence

 
• By Sue Sutter

An AI tool developed by the Office of Prescription Drug Promotion for reviews is believed to still lack generative capabilities, said former senior staffer Jason Cober, who also raised concerns about intellectual property protections for sponsors’ advertising and promotion submissions.

Off-Label Promotion: DOJ May Take New Look At Scientific Information Exchange

 
• By Sarah Karlin-Smith

Recent Justice Department filings may suggest it is rethinking allowances for drug manufacturers to communicate scientific information on unapproved uses to healthcare providers.

More from Compliance

Compounders Argue US FDA’s GLP-1 Green List Validates Legit Practices

 
• By Aakash Babu

The compounding industry said the FDA’s “green list” of GLP-1 API imports for compounded drugs validates legitimate compounding pharmacies’ role in the US health system.

FTC’s New Healthcare Division Chief Is Former Antitrust Prosecutor

 
• By Malcolm Spicer

Emma Mittelstaedt Burnham prosecuted antitrust violations in healthcare sector in her previous work at DoJ, including leading investigation into antitrust cartels in the generic pharmaceutical industry.

Under Trump, Antitrust Regulators May Be More Divestiture Friendly

 
• By Tim Casey

The Trump Administration may differ from the Biden Administration in some areas of health care antitrust enforcement, but experts said some Biden-era priorities may be maintained.